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Universitat de Barcelona, Barcelona, Spain
dDept. Biochemistry and Molecular Biomedicine. School of Biology. Universitat de Barcelona. Barcelona. Spain
e School of Chemistry. Universitat de Barcelona. Barcelona. Spain
a r t i c l e i n f o a b s t r a c tArticle history:
Received 20 May 2020
Received in revised form 15 September
2020
Accepted 16 September 2020
Available online 24 September 2020
Keywords:





Molecular dynamic simulationsBiased agonism, the ability of agonists to differentially activate downstream signaling pathways by sta-
bilizing specific receptor conformations, is a key issue for G protein-coupled receptor (GPCR) signaling.
The C-terminal domain might influence this functional selectivity of GPCRs as it engages G proteins,
GPCR kinases, b-arrestins, and several other proteins. Thus, the aim of this paper is to compare the
agonist-dependent selectivity for intracellular pathways in a heterologous system expressing the full-
length (A2AR) and a C-tail truncated (A2AD40R lacking the last 40 amino acids) adenosine A2A receptor, a
GPCR that is already targeted in Parkinson’s disease using a first-in-class drug. Experimental data such
as ligand binding, cAMP production, b-arrestin recruitment, ERK1/2 phosphorylation and dynamic mass
redistribution assays, which correspond to different aspects of signal transduction, were measured upon
the action of structurally diverse compounds (the agonists adenosine, NECA, CGS-21680, PSB-0777 and
LUF-5834 and the SCH-58261 antagonist) in cells expressing A2AR and A2AD40R. The results show that tak-
ing cAMP levels and the endogenous adenosine agonist as references, the main difference in bias was
obtained with PSB-0777 and LUF-5834. The C-terminus is dispensable for both G-protein and b-
arrestin recruitment and also for MAPK activation. Unrestrained molecular dynamics simulations, at
the ls timescale, were used to understand the structural arrangements of the binding cavity, triggered
by these chemically different agonists, facilitating G protein binding with different efficacy.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adenosine triphosphate (ATP) is the main energy-transfer
molecule and adenosine is one of its main metabolites. Adenosine
receptors appeared early in evolution, as sensors of ATP decay,
because excess of adenosine correlates with ATP depletion. They
are considered as the most ancient within the class A (or
rhodopsin-like) G-protein-coupled receptor (GPCR) family. More-
over, phylogenetic studies suggest that adenosine receptors werethe first to start diverging [1] from the MECA receptor cluster [2],
which is formed by the melanocortin, endothelial differentiation
sphingolipid, and cannabinoid receptors. There are four identified
mammalian adenosine receptors (humans included) whose cog-
nate heterotrimeric G proteins are Gi (A1 and A3) or Gs/Golf (A2A
and A2B) [3].
The crystal structure of the A2A receptor (A2AR) was one of the
first reported for the G-protein-coupled receptor (GPCR) family
[4]. Today, there are nearly fifty structures of A1R and A2AR bound
to agonists, antagonists, and/or to G proteins [5]; all of them dis-
playing the common features of class A GPCRs [6]. Unfortunately,
the N- and C-terminal domains, which are highly variable in
sequence, length, and structure [7], have been removed for crystal-
lization purposes. The long C-terminal domain of A2AR (about 122
amino acids) is known to engage G proteins, GPCR kinases, arrest-
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sible for the constitutive activity of the receptor [10], influences
the quaternary structure of heteromers [11,12], and is involved
in differential intracellular signaling [13].
A2AR offers numerous possibilities for therapeutic applications
[14–16]. A2AR antagonists show promise, among others, in Alzhei-
mer’s and Parkinson’s diseases, attention-deficit hyperactivity dis-
order, depression, and anxiety. Istradefylline, one of the most
studied antagonists, is safe and efficacious in Parkinson and was
approved in Japan as NouriastTM and by the US Food and Drug
Administration as NourianzTM [17]. A2AR agonists could be used in
Niemann Pick type C disease, autism-spectrum disorders, and
schizophrenia. Regadenoson, a selective A2AR agonists that is a
coronary vasolidator, was approved in the United States as
LexiscanTM.
These facts open the possibilities for more drug approvals, both
agonists and antagonists, related to adenosine receptors. Thus, the
aim of this work was double. First, we wanted to analyze the
agonist-dependent selectivity for intracellular pathways, known
as functional selectivity or biased agonism, using structurally
diverse compounds in a heterologous system expressing A2AR.
Biased agonists might offer attractive therapeutic properties rela-
tive to their unbiased counterpart, circumstance that remains to
be validated in clinical trials [18]. In fact, adenosine receptor biased
agonists could be used for cardioprotection without bradycardia as
a serious adverse effect [19,20]. Second, we analyzed in living cells
the effect of the C-terminal domain of A2AR in ligand binding and in
agonist-induced signaling.2. Materials and methods
2.1. Reagents
Adenosine, NECA, CGS-21680, PSB-0777, LUF-5834 and SCH-
58261 were purchased from Tocris Biosciences (Bristol, UK). HEPES
was purchased from SigmaAldrich (St. Louis, MO, US). Stock solu-
tions were prepared in DMSO. Aliquots of these stock solutions
were kept frozen at 20 C until use.2.2. Cell culture and transient transfection
Human embryonic kidney 293T (HEK-293T) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Paisley, Scot-
land, UK) supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 units/ml penicillin/streptomycin, MEM non-
essential amino acids solution (1/100) and 5% (v/v) heat inacti-
vated fetal bovine serum (FBS) [all supplements were from Invitro-
gen, (Paisley, Scotland, UK)]. Cells were incubated in a humid
atmosphere of 5% CO2 at 37 C. 24 h after seeding in 6-well or
96-well (for ERK phosphorylation assay) plates, cells were tran-
siently transfected with cDNA coding for wild-type A2AR or A2AD40R
(amino acids 372–412 on the C-terminal domain were deleted
[21]) with the PEI (PolyEthylenImine, SigmaAldrich) method as
previously described [13,22]. Truncation of this part of the C-tail
does not remove the proposed phosphorylation codes (PxPxxP/E/
D or PxxPxxP/E/D, where P represents phospho-serine or
phospho-threonine) for arrestin recruitment [23]. This phosphory-
lation code starts 33 amino acids after P7.50 of the NPxxY motif in
human rhodopsin, whereas truncation of A2AR starts 87 amino
acids after P7.50. Cells were incubated for 4 to 5 h with the cDNA
of interest, PEI and NaCl in serum-free medium. After that, the
serum-free medium was replaced by complete culture medium
and cells were incubated for 48 h at 37 C in 5% CO2 humid atmo-
sphere. The sequences in the plasmids were those coding for
human receptors. It should be noted that within a given experi-2724mental session, for instance of determination of cAMP levels, all
agonists (plus/minus antagonist when indicated) were tested in
the same batch of transfected cells.
2.3. Homogeneous HTRF binding assays
HEK-293T cells growing in 6-well plates were transiently trans-
fected with 1 mg of plasmid encoding for pHALO-tagged human
A2AR (pHALO-A2AR, Cisbio Bioassays, Codolet, France) or 1 mg of
plasmid encoding for pHALO-tagged human A2AD40R and incubated
at 37 C in a 5% CO2 humid atmosphere (24 h).
2.4. Covalent labeling of cells expressing pHALO-tagged receptors
48 h post transfection culture medium was removed, cells were
washed with PBS and incubated with 100 nM of HALO-Lumi4Tb, a
terbium derivative of O6-benzylguanine (SSNPTBC, Cisbio Bioas-
says, Codolet, France) - previously diluted in TagLite Buffer (TLB)
(LABMED, Cisbio Bioassays, Codolet, France) for 1 h at 37 C under
5% CO2 humid atmosphere. After that, cells were washed with PBS
to remove the excess of HALO-Lumi4Tb, detached with Versene
(Gibco Life Technologies, Paisley, Scotland, UK), centrifuged at
1,500 rpm for 5 min and resuspended in TLB. Densities of 10,000
cells/well were used to carry out binding assays in white opaque
384-well plates.
2.5. Non-radioactive homogeneous time-resolved FRET-based binding
assays
Saturation binding experiments were performed by incubating
cells expressing Tb-labeled HALO-A2AR with increasing concentra-
tions of the A2AR antagonist SCH-442416, conjugated to a fluores-
cent probe developed by Cisbio (red A2AR ligand, purchased from
Cisbio Bioassays, Codolet, France). The unspecific signal was
obtained by incubating cells expressing Tb-labeled HALO-A2AR
with increasing concentrations of red A2AR ligand in the presence
of 10 mM unlabeled SCH-58261. Both, fluorescent ligands and unla-
beled compounds, were diluted in TLB. 10 ml of labeled cells
(10,000 cells/well) were loaded onto 384-well white plates and
5 ml unlabeled SCH-58261 (10 mM final concentration) or TLB were
added, followed by the addition of 5 ml of increasing concentrations
(0–60 nM range) of red A2AR ligand. Plates were incubated pro-
tected from light for 2 h at room temperature before time-
resolved fluorescence resonance energy transfer (TR-FRET) signal
reading. The specific binding was calculated by subtracting the
unspecific binding from the total binding.
For competition binding assays, HEK-293T cells transiently
expressing Tb-labeled HALO-A2AR, or A2AD40R, were incubated with
20 nM fluorophore-conjugated A2AR ligand, in the presence of
increasing concentrations (0–10 mM range) of agonists (or antago-
nists when indicated). Plates contained 10 ml of labeled cells, and
5 ml of tested compounds or TLB were added prior to the addition
of 5 ml of the red A2AR ligand. Plates were then incubated for at
least 2 h at room temperature prior to TR-FRET signal detection.
Detailed description of the HTRF assay is found elsewhere [24].
2.6. Signal detection and data analysis
Signal was detected using a PHERAstar FS (BMG Lab technolo-
gies, Offenburg, Germany) microplate reader equipped with a FRET
optic module allowing donor excitation at 337 nm and signal col-
lection at both 665 and 620 nm. A frequency of 10 flashes/well was
selected for the xenon flash lamp excitation. The signal was col-
lected at both 665 and 620 nm using the following time-resolved
settings: delay, 150 ms; integration time, 500 ms. HTRF ratios were
obtained by dividing the acceptor signal (665 nm) by the donor sig-
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multiplying factor is used solely for the purpose of easier data
handling.
Data were analyzed using Prism 7 software (GraphPad Soft-
ware, Inc., San Diego, CA), and competition data were fitted by
non-linear regression to a one site-fit logIC50, competition curves
were -in all cases- monophasic. KD (dissociation constant) values
of the fluorescent ligand were obtained from the specific binding
saturation curves. Note that Bmax values obtained from HTRF satu-
ration curves do not reflect absolute values of receptor binding
sites. Ki values were determined from competition binding assays
by using the calculated IC50 and KD values and the Cheng-Prusoff
equation [25].2.7. cAMP determination
HEK-293T cells were grown in 6-well plates and transiently
transfected with cDNAs for A2AR or for A2AD 40R as described in 2.2.
Two hours before initiating the experiment, medium was replaced
by serum-free DMEM medium. Then cells were detached, isolated
by centrifugation (5 min at 1,500 rpm) and resuspended in DMEM
containing 50 mM zardaverine (phosphodiesterase inhibitor) to
prevent degradation of cAMP, and 5 mMHEPES (pH 7.4). Cells were
placed in white 384-well plates (PerkinElmer) (6,000 cells/well)
and incubated with antagonists or vehicle for 15 min before treat-
ment with agonist or vehicle for 15 min. Finally, cAMP-Eu and the
fluorescent antibody were added. Readings were performed after
one hour incubation at 25 C. Homogeneous time-resolved fluores-
cence energy transfer (HTRF) measures were performed using the
Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, US). Fluores-
cence at 665 nm was measured in a PHERAstar Flagship plate
reader equipped with an HTRF optical module (BMG Lab technolo-
gies, Offenburg, Germany).2.8. ERK1/2 phosphorylation assays
HEK-293T cells were grown on transparent Biocat Poly-D-
Lysine 96-well plates (Deltalab) and kept at the incubator for
24 h. Then cells were transiently transfected with cDNA coding
for A2AR or A2AD40R and incubated for 48 h at 37 C in a 5% CO2
humid atmosphere. Supplementary Fig. S1A shows that treatment
with CGS-21680 in non-transfected HEK-293T cells is not signifi-
cantly different to the basal condition. Thus, the expression level
of A2AR in non-transfected HEK-293T cells is negligible. 2 h before
initiating the experiment, the medium was substituted by serum-
free DMEM. Cells were stimulated at 25 C for 10 min with vehi-
cle or agonists (Supplementary Fig. S1D). ERK phosphorylation
was measured at ‘‘short” times to detect G-protein mediated sig-
nal. After that, cells were washed twice with cold PBS before the
addition of lysis buffer (30 ml/well; Perkin Elmer, Waltham, MA,
US) and incubated for 15 min at 25 C on a Heidolph Titramax
100 shaker. 10 ml of each cell lysate was transferred to white
ProxiPlate 384-well microplates (PerkinElmer; Waltham, MA,
USA). ERK1/2 phosphorylation was determined using AlphaS-
creenSureFire kit (Perkin Elmer, Waltham, MA, US): 5 ml/well
of acceptor beads were added. Plates, protected from light, were
incubated for 2 h at 25 C. Finally, 5 ll/well of donor beads were
added and plates, protected from light, were incubated for 2 h
before analysis. Fluorescence was determined using an EnSpire
Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The
value of reference (100%) was that achieved in the absence of
any treatment (basal). The effect of ligands was given in percent-
age respect to the basal value.27252.9. b-Arrestin 2 recruitment
HEK-293T cells were transiently transfected with 0.625 mg of
cDNA coding for b-arrestin 2-Rluc and 2 mg of cDNA coding for
A2A-YFP or with 1.5 mg of cDNA coding for b -arrestin 2-Rluc and
4 mg of cDNA coding for A2AD40R-YFP. BRET experiments were per-
formed 48 h after transfection. Cells were detached using HBSS
containing 0.1% glucose, centrifuged for 5 min at 3,200 rpm and
resuspended in the same buffer. Protein concentration was quanti-
fied by using the Bradford assay kit (Bio-Rad, Munich, Germany).
Hereafter, YFP fluorescence at 530 nm was quantified in a FluoStar
Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany)
to quantify receptor-YFP expression. To measure b -arrestin
recruitment, cells (20 mg of protein) were distributed in 96-well
microplates (Corning 3600, white plates with white bottom) and
were incubated for 10 min with antagonists. Cells were then stim-
ulated with agonists prior to the addition of 5 mM Coelenterazine H
(Molecular Probes, Eugene, OR). BRET between b-arrestin 2-Rluc
and receptor-YFP was determined and quantified at 5 min after
adding coelenterazine H. This time of response was selected from
time-response curves (Supplementary Fig. S1C). The readings were
collected using a Mithras LB 940 (Berthold Technologies, Bad Wild-
bad, GE), which allows the integration of the signals detected in the
short-wavelength filter (485 nm) and the long wavelength filter
(530 nm). To quantify protein-RLuc expression, luminescence
readings were also collected 10 min after the addition of 5 mM coe-
lenterazine H.
2.10. Dynamic mass redistribution assays (DMR)
Cell mass redistribution induced upon receptor activation was
detected by illuminating with polychromatic light the underside
of a biosensor and measuring the changes in the wavelength of
the reflected monochromatic light, that is a sensitive function of
the index of refraction. The magnitude of the wavelength shift
(in picometers) is directly proportional to the amount of mass
redistribution. 48 h before the assay, HEK-293T cells were tran-
siently transfected with 2 mg of cDNA coding for A2AR or A2AD40R.
HEK-293T cells were seeded in 384-well sensor microplates to
obtain 70–80% confluent monolayers constituted by approximately
10,000 cells/well. Prior to the assay, cells were washed twice with
assay buffer (HBSS with 20 mM HEPES, pH 7.15 and 1% BSA) (Sig-
maAldrich, St. Louis, MO, US) and incubated for 2 h with assay-
buffer containing 0.1% DMSO (24 C, 30 ml/well). Hereafter, the sen-
sor plate was scanned, and a baseline optical signature was
recorded for 10 min before adding 10 ml of the selective antagonists
for 30 min, followed by the addition of 10 ml of the selective ago-
nists; all test compounds were diluted in assay buffer. Then,
DMR responses were monitored for at least 5000 s in an EnSpire
Multimode Plate Reader (PerkinElmer, Waltham, MA, USA) by a
label-free technology. Results were analyzed using EnSpire Work-
station Software v 4.10.
2.11. Calculation of bias factor
Bias factor (bias) was calculated with the following formulas
adapted from [26] in which s represents the agonist efficacy, and
KA the agonist affinity [27].
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mously as logR, a parameter that can be used to compare agonist
activity between different systems. The transduction coefficient
is a measure of the ability of a ligand to activate the receptor [28].
The pathway of reference j1 was cAMP determination for Gs-
coupling, whereas the other pathways (ERK1/2 phosphorylation,
ß-arrestin 2 recruitment, or DMR) were j2. s denotes the maximum
value in each response and KA is the antilogarithm of half maximal
effective concentration (EC50 if the agonist provides an increase
response, IC50 if the agonist provides a reduction of the response
induced by another reagent).
2.12. Computational methods
Preparation of protein structure and ligand parametrization. Crys-
tal structures of the A2AR in its active intermediate state in com-
plex with the adenosine (PDB id 2YDO), NECA (2YDV) and CGS-
21680 (4UHR) agonists, and the crystal structure of A2AR in its
inactive state in complex with the ZM241385 antagonist (PDB id
4EIY) were obtained from the Protein Data Bank (rcsb.org). Fusion
proteins were removed and stabilizing mutations were mutated to
the native sequence using MODELLER v9.12 [29]. Parameters for
adenosine, NECA, CGS-21680, PSB-0777, LUF-5834 and SCH-
58261 were obtained from the general Amber force field (GAFF)
and HF/6-31G*//HF/6-31G*-derived RESP atomic charges calcu-
lated with Gaussian09.
Molecular docking. The PSB-0777 and LUF-5834 agonists were
docked into the active intermediate state (2YDV) and the SCH-
58261 antagonist was docked into the inactive state (4EIY) using
the Molecular Operating Environment (MOE) software (Chemical
Computing Group Inc., Montreal, Quebec, Canada). One hundred
docking solutions per ligand were generated by the triangle
matcher algorithm into the active site of the receptor structures.
Top-ranking solutions were inspected and conformations in which
the central moiety of PSB-0777 and the aminopyridine group of
LUF-5834 were located in the same region as the adenine moiety
of adenosine and NECA were selected (Supplementary Fig. S2).
The binding pose of SCH-58261 was selected in such a manner that
the orientation of its pyrazolo-triazolo-pyrimidine central moiety
was similar to the bicyclic triazolotrazine core of the highly potent
selective antagonist ZM241385 found in the 4EIY structure (Sup-
plementary Fig. S2).
Molecular dynamics (MD) simulations. The complexes of adeno-
sine, NECA, CGS-21680, PSB-0777 and LUF-5834 with the interme-
diate active structure of A2AR and the complex of SCH-58261 with
the inactive structure of A2AR (see above) were embedded in a pre-
equilibrated lipid bilayer box containing 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphatidylcholine (POPC), water molecules (TIP3P)
and monoatomic Na + and Cl ions (0.2 M). Assignment of ioniza-
tion states and hydrogens at physiological pH for the selected
structures was conducted with the Protonate3D method [30] as
implemented in MOE. D2.50 was deprotonated (negatively
charged) for antagonist-bound receptor simulations and proto-
nated (neutral) for agonist-bound receptor simulations [31],
whereas H264 was protonated (positively charged) in all simula-
tions [32]. A sodium ion was placed, near the negatively charged
D2.50, in the inactive, antagonist-bound, structure of A2AR
[33,34]. Molecular systems were subject to a 1000 cycles of energy
minimization, followed by 20 ns of gradual relaxation of positional
restraints (corresponding to 100, 50, 25 and 10 kJ.mol1nm2) at
protein backbone coordinates before the production phase in order
to hydrate the receptor cavities and allow lipids to pack around the
protein. After equilibration, unrestrainedMD simulation (3 replicas
of 1 ls giving a total of 3 ls of sampling time) were produced for
each ligand-receptor complex at a constant temperature of 300 K
using separate v-rescale thermostats for the receptor, ligands,2726lipids and solvent molecules. A time step of 2.0 fs was used for
the integration of equations of motions. All bonds and angles were
kept frozen using the LINCS algorithms. Lennard-Jones interactions
were computed using a cutoff of 10 Å, and the electrostatic inter-
actions were treated using PME with the same real-space cutoff
under periodic boundary conditions. MD simulations were per-
formed using GROMACS v5.0.7. The AMBER99SB force field as
implemented in GROMACS, Berger parameters for POPC lipids,
and the GAFF parameters for the ligands (see above) were used
for the MD simulations, attending the performance of this protocol
on membrane-protein systems [35].
2.13. Statistical analysis
Experimental data was managed and analysed with GraphPad
Prism software version 7 (San Diego, CA, USA) or IBM SPSS Statis-
tics version 25.0 (IBM Corp., NY, USA). Unless otherwise stated data
are the mean ± S.E.M (n = 5 or higher). P-values lower than 0.05
were considered statistically significant.3. Results and discussion
3.1. Ligand binding experiments
We studied the binding of the agonists adenosine, NECA and
CGS-21680, the partial agonists PSB-0777 and LUF-5834, and the
selective antagonist SCH-58261 by homogeneous time-resolved
fluorescence (HTRF) experiments, schematized in Fig. 1A, in living
HEK-293T cells expressing either wild type (wt) A2AR or a trun-
cated receptor (A2AD40R, lacking the last 40 amino acids of the C-
terminal end) tagged with HaloTag on the N-terminus (see 2.3–
2.5). First, a saturation curve was performed using a
fluorescence-conjugated antagonist (Fig. 1B). The obtained KD val-
ues were 1.7 nM and 1.2 nM for full-length A2AR and A2AD40R, respec-
tively (Table 1). Subsequently, competition assays were performed
using 20 nM of the fluorescence-conjugated antagonist and
increasing amounts of the ligands (Fig. 1C-1D). The Ki value of each
compound was calculated from IC50 and KD values using the Cheng-
Prusoff expression [25] (Table 1). The obtained Ki values are in the
range of those obtained in radioligand binding assays for isolated
membranes from tissues or transfected cells. According to this
assay, the Ki values of agonists are in the 13–219 nM range, LUF-
5834 being the compound that binds A2AR the strongest and
PSB-0777 the weakest. Clearly, removal of the C-terminal domain
results in weaker agonist binding to the orthosteric site (a ratio
of Ki values in the 1.4–4.4 range, which correspond to binding free
energy differences between 0.2 and 0.9 Kcal/mol). On the other
hand, removal of the C-terminal domain has a significant impact
on the binding of the antagonist SCH-58261 (0.7 nM vs 113.9 nM
for full-length A2AR and A2AD40R, respectively; binding free energy
difference of 3.0 Kcal/mol).
3.2. Molecular models of agonist binding
The binding of these compounds to A2AR has been extensively
studied by site-directed mutagenesis, computer simulations, and
supported by the recent crystallographic data of adenosine, NECA
and CGS in complex with A2AR (reviewed in [36]). PSB-0777 and
LUF-5834 were docked (see 2.12) using, as template, ligands solved
in crystal structures with homologous chemical scaffolds (see Sup-
plementary Fig. S2). All molecules but LUF-5834 are structurally
related through a common adenosine core. Fig. 2 summarizes the
binding modes of all compounds, emphasizing common/different
areas of the receptor occupied by each ligand. In order to under-
stand the molecular mechanism of receptor activation (see 3.5),
Fig. 1. Competition curves in HTRF-based assays. Panel A: Scheme of the homogeneous binding technology performed in living HEK-293T cells. Panel B. Saturation isotherm
of binding of fluorophore-conjugated red A2AR ligand to HEK-293T cells transiently transfected with HALO-A2AR in the absence (red) or presence of 10 mM SCH-58261 (black);
specific binding is depicted in green. Panels C-D: Non-radiolabeled HTRF-based competition curves of specific binding of 20 nM fluorophore-conjugated red A2AR ligand in the
presence of increasing concentrations of different agonists and of the selective antagonist SCH-58261, in cells expressing A2AR (C) or A2AD40R (D). Data represent the
mean ± SEM of a representative experiment (n = 4). HTRF ratio = (665 nm acceptor signal/620 nm donor signal)  10,000. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
Table 1
IC50 and Ki values obtained from competition binding assays in HEK-293T cells
expressing wild type A2AR or A2AD40R. Values reported are the mean of three














adenosine 1658 183 4804 531 2.9 0.6
NECA 1118 124 2190 242 2.0 0.4
CGS-21680 746 82.5 1690 187 2.3 0.5
PSB-0777 1984 219 8680 960 4.4 0.9
LUF-5834 115 13 166.0 18 1.4 0.2
SCH-58261 6.3 0.7 1030 114 162.3 3.0
A2AR A2AD40R
Bmax KD (nM) Bmax KD (nM)
6959 1.677 9214 1.22
aExperimental binding free energy differences between wild type (A2AR) and
truncated (A2AD40R) receptors, calculated as DDG = -RT ln (KiDCT/Kiwt) where R is
1.987 cal mol1 K1 and T is the temperature of 298K (-RT = 0.592 kcal mol1)
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interactions of crucial ligand moieties to key receptor amino acids
in all these regions. Detailed analysis of the simulations shows that
these binding modes were stable during the unbiased 1 ls MD
simulations (three replicas) as shown by the relatively low move-
ment in root mean-square deviation (rmsd) plots of the receptor
and ligand heavy atoms, as well as the conservation of the sec-
ondary structure elements of A2AR (Supplementary Figs. S3-S5).2727As shown in Fig. 2, three regions (blue, green and yellow rectan-
gles) are invariably occupied by functional groups of all the studied
compounds, illustrated by the binding of adenosine in the central
panel. The heterocyclic site (blue rectangle) corresponds to the
central region and accommodates the adenine moiety of adeno-
sine, NECA, CGS-21680, and PSB-0777, and the aminopyridine
group of LUF-5834 through aromatic/hydrophobic interactions
with F168, M5.38, M7.35, I7.39 (numbering in Ballesteros and
Weinstein scheme [37], except for residues outside helices in
which sequence numbers are used) and polar interactions of the
exocyclic nitrogen with N6.55 (Supplementary Fig. S3). The second
region (green rectangle) accommodates the 50-hydroxymethyl
(adenosine and PSB-0777), N-ethylcarboxamido (NECA and CGS-
21680) and hydroxyphenyl group of LUF-5834 (Fig. 2). The 50-
hydroxymethyl group attached to the ribose ring of adenosine
and PSB-0777 and the hydroxyphenyl group of LUF-5834 hydrogen
bond H6.52 during all the simulation time (Supplementary Fig. S3).
NECA and CGS-21680 replace the 50-hydroxymethyl group by the
longer N-ethylcarboxamido group that can directly interact with
both H6.52 and T3.36 (Supplementary Fig. S3). Several X-ray struc-
tures of A2AR contain crystallized water molecules in the environ-
ment of T3.36 and N5.42 [4] that are important for the activity of
GPCRs [38,39]. Supplementary Fig. S6 shows that during the MD
simulations adenosine, PSB-0777 and LUF-5834 maintain this
water bridge, whereas NECA and CGS-21680 cannot because the
N-ethylcarboxamido group interacts with T3.36. Finally, the third
region (yellow rectangle) is occupied by the ribose moiety of ade-
nosine derivatives and by the carbonitrile substituent of LUF-5834.
Most important interactions in this site imply the formation of
Fig. 2. Ligand-receptor complexes. Cross-section through the A2AR, highlighting the agonists adenosine (white sticks), NECA (cyan), CGS-21680 (pink), PSB-0777 (green) and
LUF-5834 (blue) occupying the binding site. Color rectangles highlight regions of the orthosteric binding cavity that are occupied by functional groups of the studied agonists
(see 3.2). The PIF motif (in yellow) located below the orthosteric binding cavity, and the side chain of the highly conserved R3.50 (in green) of the DRY motif near the G protein
binding site are highlighted. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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of the ribose moiety of adenosine derivatives with the S7.42 and
H7.43 residues.
Three additional regions are occupied by the ligands (orange,
cyan and black in Fig. 2). The ethyl group of the N-
ethylcarboxamido moiety of NECA and CGS-21680 extends deep
into the binding pocket (orange), forming hydrophobic interactions
with C5.46 (Supplementary Fig. S3). These interactions between
aliphatic chains and sulfur-containing amino acids have been
shown to be of high energy [40]. The long substituents of CGS-
21680 and PSB-0777 expand toward the extracellular loops
through a cavity within TMs 1, 2 and 7 (black rectangle), which
has been shown to influence G protein and b-arrestin signaling in
other GPCRs [41,42]. The negatively charged SO3 group of PSB-
0777 interacts with His264 in ECL3, whereas the longer chain of
CGS-21680 permits the negatively charged COO to form an ionic
interaction with K153 in ECL2 (Supplementary Fig. S7). Finally, the
imidazole substituent of LUF-5834 interacts with residues Y1.35,
A2.61, I2.64, S2.65, and I7.39 in the sideward region of the binding
cavity (cyan rectangle). This binding orientation of LUF-5834 has
been previously proposed using mutagenesis studies [43]. This
region is generally occupied by inverse agonists and, thus, we
believe contributes to the low activity of LUF-5834 regarding the
rest of the agonists.
3.3. Agonist-induced signaling responses
Next, we measured four functional read-outs that correspond to
different steps of the signaling pathways in cells expressing full-
length A2AR or A2AD40R: cAMP production, b-arrestin recruitment,
ERK1/2 phosphorylation, and dynamic mass redistribution (DMR)
assays (Fig. 3 and Table 2). Immediately following receptor activa-
tion, cAMP levels increase as the result of adenylyl cyclase activa-
tion by Gs. Next, receptor phosphorylation by G protein kinases
triggers b-arrestin recruitment. Later, ERK signaling is regulated
by G protein or/and b-arrestin. DMR accounts for events that occur2728much later in the signaling pathway such as protein trafficking,
rearrangement of cytoskeleton and adhesion or morphological
changes. The amount of transfected cDNA for A2AR and A2AD40R
was adjusted to obtain similar receptor expression levels (Supple-
mentary Fig. S1B). b-arrestin recruitment and ERK1/2 phosphoryla-
tion were analyzed by time response curves (Supplementary
Figs. S1C-S1D). In our cAMP assay conditions, adenosine, NECA,
and CGS-21680 behaved as full agonists, whereas PSB-0777 and
LUF-5834 were partial agonists on full-length A2AR. The effect
was specific for all agonists as shown by the blockade of cAMP pro-
duction using the selective receptor antagonist SCH-58261 (Sup-
plementary Fig. S8). b-arrestin recruitment assays showed that
PSB-0777 and NECA are more efficient in recruitment than adeno-
sine and CGS-21680. Remarkably, LUF-5834, which is a partial ago-
nist in the cAMP assay, is as efficient as CGS-21680 and adenosine
in b-arrestin recruitment. pERK1/2 dose–response curves follow
similar patterns as cAMP curves, with the exceptions of PSB-0777
that behaves as a full agonist, and LUF-5834 that is a very weak
partial agonist. DMR responses were all very similar with PSB-
0777 providing a slightly larger signal at higher concentrations.
In agreement with previous reports [10], removal the last 40
amino acids of the C-terminus in the A2AD40R construct caused a
right-shift of the cAMP dose–response curves (a ratio of EC50 values
in the 2.2–9.8 range, similar to the range of Ki ratios) with almost
no change in Emax for all agonists, with the exception of LUF-
5834 whose effect became almost negligible in the truncated form
of the receptor (Fig. 3 and Table 2). C-terminal truncation provides
a small decrease in b-arrestin recruitment with no changes in Emax
rank order relative to full-length A2AR. pERK1/2 dose–response
curves of A2AD40R were very similar to full-length A2AR except that
pEC50 increased for the truncated receptor, which goes against
the general trend, and the potency of NECA and PSB-0777 became
close to that of adenosine and CGS-21680. Finally, DMR read-outs
of A2AD40R were almost negligible for NECA and adenosine while we
could observe a higher signal for PSB-0777 compared to that of the
other compounds in A2AR and A2AD40R.
Fig. 3. Signaling in cells expressing either A2AR or A2AD40R. Dose response curves on
0.5 mM forskolin-induced cAMP levels, on ß-arrestin recruitment, on ERK1/2
phosphorylation, and on dynamic mass redistribution (DMR). Data (n = 12, each in
triplicates) for cAMP are given in percentage (100% represents the forskolin effect).
Data (n = 10, each in triplicates) for BRET assays, used to determine b-arrestin
recruitment, are given in milliBRET Units (mBU). Data (n = 6, each in triplicates) for
ERK1/2 phosphorylation are expressed as % with respect to basal levels. DMR
tracings are representing the picometer (pm)-shifts of reflected light wavelengths
over time upon ligand treatment.
G. Navarro, A. Gonzalez, S. Campanacci et al. Computational and Structural Biotechnology Journal 18 (2020) 2723–27323.4. Addressing biased agonism
Bias factors were calculated taking as reference the effect of
adenosine, the endogenous compound, and the Gs-mediated sig-Table 2
pEC50 and Emax values obtained in HEK-293T cells expressing wild type A2AR or truncate
dynamic mass redistribution (DMR) response (Fig. 3).
cAMP assays b -arrestin assays
A2AR A2AD40R A2AR A2AD40R
pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Em
Adenosine 8.0 156.6 8.1 163.5 7.8 24.1 7.7 23
NECA 9.0 156.6 9.0 166.0 7.9 34.9 7.8 31
CGS-21680 8.0 155.1 8.2 163.4 7.9 25.9 7.8 26
PSB-0777 8.1 127.7 8.6 133.5 7.9 37.6 7.7 33
LUF-5834 9.7 131.1 8.2 113.6 8.0 27.8 7.8 28
2729nal, i.e. cAMP response elicited by adenosine (see 2.8). Bias factors
for CGS-21680, PSB-0777, LUF-5834 and NECA agonists in cAMP, b-
arrestin recruitment, ERK1/2 phosphorylation and DMR signaling
responses are summarized in the radar plot of Fig. 4. Adenosine
and CGS-21680 are balanced agonists with similar bias factors
for the four pathways, whereas NECA has small factors for DMR
and b-arrestin recruitment and LUF-5834 has small factors for all
responses other than cAMP. By contrast, PSB-0777 has a higher
bias for the pERK1/2 response. Truncation of the C-terminus makes
LUF-5834 and PSB-0777 more balanced. In fact, LUF-5834 acquires
the largest bias factors for b-arrestin recruitment, ERK1/2 phospho-
rylation and DMR. By contrast, NECA keeps the small factors for b-
arrestin recruitment and DMR. Overall the results are consistent
with the C-terminus being dispensable for both G-protein and
arrestin recruitment and also for MAPK activation (ERK1/2 phos-
phorylation and DMR), with only minor differences in signaling
compared to full-length A2AR.3.5. Molecular mechanisms of agonist-induced receptor activation
The first step to understand the mechanisms of agonist-induced
receptor activation, was to compare by MD simulations the trajec-
tories of amino acids at positions 3.40, 5.50, and 6.44 (Fig. 5), which
have been named as the ‘‘P-I-F” motif [44], the ‘‘transmission
switch” [45], the ‘‘triad core” [46] or the connector region [6], in
the presence of the agonists adenosine, NECA, CGS-21680, PSB-
0777 and LUF-5834 and the antagonist SCH-58261. These residues,
located below the ligand binding cavity and above the G protein or
arrestin binding cavity (see Fig. 2), adopt different positions upon
binding of agonists or antagonists [47,48], and we have been using
them to predict the effect of the ligand on the conformational state
of the receptor [49–51]. Clearly, the agonist-bound, active-like
complexes are characterized relative to the antagonist-bound,
inactive-like, complex by the proposed inward movement of TM5
at the highly conserved P5.50, rotation of TM3 due to a steric clash
with the bulky I3.40, and an outward movement of F6.44 in TM6
(Fig. 5). Unfortunately, these movements are similar for full and
partial agonists and cannot be used to explain the different agonist
pharmacological profiles.
Thus, in order to understand the structural arrangements of the
binding cavity, triggered by these chemically different agonists,
facilitating G protein binding or b-arrestin recruitment with differ-
ent efficacy, we studied the trajectories of a selected group of 34
amino acids either located above (in the ligand binding cavity)
and below (in the G protein or arrestin binding cavity) the ‘‘trans-
mission switch” amino acids in the presence of agonists and the
antagonist (see Supplementary Table S1). In the bivariate correla-
tion analysis, dependent variables are Emax values measured in
cAMP production and b-arrestin recruitment, whereas indepen-
dent variables are the movement of the chosen amino acid in the
agonist-bound, active-like complexes relative to the antagonist-
bound, inactive-like complex. This is measured as the distanced A2AD40R for cAMP production, b-arrestin II recruitment, ERK1/2 phosphorylation and
pERK1/2 assays DMR assays
A2AR A2AD40R A2AR A2AD40R
ax pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax
.7 7.5 373.0 7.7 326.9 6.4 1231 6.4 517.8
.3 8.3 392.1 8.2 302.6 6.4 1416 6.5 407.9
.8 7.4 373.5 7.7 315.2 6.4 1374 6.4 941.5
.8 8.5 374.7 8.3 300.7 6.2 1887 6.2 1332
.0 8.2 183.9 8.2 175.8 6.3 1306 6.3 988.6
Fig. 4. Radar plot representation of bias factors. Plots show the bias factors of the different compounds in the different functional outcomes in cells expressing A2AR or A2AD40R.
Adenosine and the Gs-cAMP signaling pathway were used as reference for calculations.
Fig. 5. Receptor side-chain movements in response to agonists. Plot of the centroids (calculated from 100 snapshots) of the Cb atoms of a selected group of 34 amino acids
(Table S1) located above (in the ligand binding cavity) and below (in the G protein or b-arrestin binding cavity) the ‘‘transmission switch” amino acids obtained during 1 ls of
MD simulations of A2AR in the presence of the agonists adenosine, NECA, CGS-21680, PSB-0777 and LUF-5834 and a selective antagonist SCH-58261. The distances between
the centroids of the agonist-bound conformations and the centroid of the antagonist-bound conformation were statistically correlated with Emax values measured in cAMP
production and b-arrestin recruitment (Table S1). (A) Movement of the salt bridge between E169ECL2 and H264ECL3 that is proposed to govern the residence time of ligands. (B)
Movement of E131.39, and the nearby H2787.43, that correlates with b-arrestin recruitment. (C) The proposed mechanism of receptor activation at the ‘‘transmission switch”
amino acids (inward movement of TM 5, an anticlockwise rotation of TM 3, and an outward movement of TM 6, see arrows) is observed but similar for full and partial
agonists. (D) Movement of T883.36 and W2466.48 that correlate with cAMP production (Supplementary Fig. S9).
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during 1 ls of unbiased MD simulations) of the Cb positions of
the chosen amino acids of A2AR bound to agonists and the centroid
of A2AR bound to the antagonist. No deviations from normality
(Shapiro-Wilk test) are observed in all variables, thus, correlation
analyses were performed using a Pearson test for continuous, nor-
mally distributed variables.
Although ligand efficacy is a function of multiple factors, we
found a clear statistically significant correlation between Emax in
cAMP assays and the movement of the side chains of T3.36
(p = 0.033) and W6.48 (p = 0.015) above the ‘‘transmission switch”2730and Y5.58 (p = 0.039) below the ‘‘transmission switch” (Supple-
mentary Table S1). Y5.58 is a key amino acid in the process of
receptor activation as it stabilizes the extended conformation of
R3.50 in the active state [52]. Positions 3.36 and 6.48 have been
described as conformational toggle or trigger switches involved
in the initial agonist-induced receptor activation in other GPCRs
such as cannabinoid CB1R [53,54], serotonin 5HT4R [55], melano-
corin MC4R [56], mGlu2R [57], or A2AR [58]. With the aim of under-
standing at the molecular level the different activation trends
among agonists, we explored the amount of time, in the MD sim-
ulations, the side chains of T3.36 and W6.48 spend in the gauche
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formations (see Supplementary Fig. S9). Clearly, the antagonist-
bound structure favors the g+/g+ conformations of T3.36 and
W6.48, whereas full agonists adenosine, NECA, and CGS-21680
favor the g-/g+ conformations. Notably, partial agonists PSB-0777
and LUF-5834 cannot achieve these g-/g+ conformations as fre-
quently as full agonists. In this respect, it should be noted that
Thr residues in this g- conformation are capable of hydrogen bond-
ing the backbone carbonyl in the previous turn of the helix, which
is known to trigger a local opening of the helix [59] that might be
necessary for receptor activation. Importantly, the T3.36A muta-
tion impedes signaling [43,60] and the W6.48A mutation has sig-
nificant deleterious effects on receptor function [43].
In the case of Emax in b-arrestin recruitment, we found a statis-
tically significant correlation only with the movement of the side
chain of E1.39 (p = 0.014) above the ‘‘transmission switch” (Supple-
mentary Table S1). Because E1.39 and H7.43 might form an ionic
interaction we calculated the distance between these side chains
in the presence of the different agonists. However, we have not
observed a statistically significant correlation between this dis-
tance and Emax in b-arrestin recruitment.
4. Conclusion
The agonist-dependent selectivity for intracellular pathways of
A2AR has been studied using, in synergy, molecular modeling tools
and pharmacological assays. This combination of expertise has per-
mitted to understand the structural arrangements of the binding
cavity, triggered by chemically different agonists, facilitating G
protein binding with different efficacy. The mechanism of
agonist-induced b-arrestin recruitment seems more difficult to
rationalize. First, different ligands stimulation might induce dis-
tinct patterns of receptor phosphorylation, which direct specific
b-arrestin conformations and functional outcomes [61–63]. Sec-
ond, there is increasing evidence that biased signaling could also
be a consequence of binding kinetics [64–66]. In particular, a rela-
tion between residence time of ligands with biased signaling in
both A1R and A2AR [67,68] that is governed by a salt bridge
between E169ECL2 and H264ECL3 in A2AR (Fig. 5A) [69,70] has been
shown. Finally, the last 40 amino acids of the C-terminal end of
A2AR receptor are dispensable for both G-protein and arrestin
recruitment and also for MAPK activation (ERK1/2 phosphorylation
and DMR).
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